Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Copeland, L. A. Articles by Blow, F. C. Search for Related Content PubMed Citation Articles by Copeland, L. A. Articles by Blow, F. C. Minority Issues Other Patient Groups/Issues Atypical Neuroleptics Related Article

Racial Disparity in the Use of Atypical Antipsychotic Medications Among Veterans

OBJECTIVE: This study assessed the current state of antipsychotic prescription practices regarding race among veterans receiving care through the Department of Veterans Affairs. METHOD: The authors examined pharmacy records over a 12-month period for all veterans with schizophrenia and antipsychotic prescriptions in fiscal year 1999. They used logistic regression analysis to assess the effect of race on the use of various atypical antipsychotic agents. Analytic models controlled for age, sex, comorbid substance use, bipolar disorder, and other psychosis. RESULTS: The sample of 69,787 veterans with schizophrenia was 61.3% white, 30.1% African American, and 8.5% Hispanic. Among them, 39% had prescriptions for conventional antipsychotics, 37% for atypical antipsychotics, and 23% for both atypical and conventional antipsychotics. Use of any atypical agent during the year was less likely for Hispanic veterans (55%) than for two other groups (both 61%). When examining specific medications in a multivariate model, the authors found that African American and Hispanic veterans were much less likely to receive clozapine than were white veterans. CONCLUSIONS: Overall use of atypical antipsychotics was slightly less common for African American and Hispanic veterans with schizophrenia than for white patients. However, use of clozapine, the first choice for refractory illness and possibly uniquely effective for patients with comorbid substance abuse, did vary greatly by race. This may reflect concern over serious side effects, such as loss of white blood cells and fluctuations of serum glucose levels, or patient preference.

Related Article:

In This Issue
Am J Psychiatry 2003 160: A62. [Full Text] [PDF]

This article has been cited by other articles:

				C. M. Rousseau, G. N. Ioannou, J. A. Todd-Stenberg, K. L. Sloan, M. F. Larson, C. W. Forsberg, and J. A. Dominitz Racial Differences in the Evaluation and Treatment of Hepatitis C Among Veterans: A Retrospective Cohort Study Am J Public Health, May 1, 2008; 98(5): 846 - 852. [Abstract] [Full Text] [PDF]

				D. L. Kelly, J. Kreyenbuhl, L. Dixon, R. C. Love, D. Medoff, and R. R. Conley Clozapine Underutilization and Discontinuation in African Americans Due to Leucopenia Schizophr Bull, September 1, 2007; 33(5): 1221 - 1224. [Abstract] [Full Text] [PDF]

				A. Connolly, P. Rogers, and D. Taylor Antipsychotic prescribing quality and ethnicity -- a study of hospitalized patients in south east London J Psychopharmacol, March 1, 2007; 21(2): 191 - 197. [Abstract] [PDF]

				M. Valenstein, J. F. McCarthy, K. L. Austin, J. F. Greden, E. A. Young, and F. C. Blow What Happened to Lithium? Antidepressant Augmentation in Clinical Settings Am J Psychiatry, July 1, 2006; 163(7): 1219 - 1225. [Abstract] [Full Text] [PDF]

				M. Valenstein, J. F. McCarthy, R. V. Ignacio, G. W. Dalack, T. Stavenger, and F. C. Blow Patient- and Facility-Level Factors Associated With Diffusion of a New Antipsychotic in the VA Health System Psychiatr Serv, January 1, 2006; 57(1): 70 - 76. [Abstract] [Full Text] [PDF]

				A. M. Kilbourne, M. S. Bauer, X. Han, G. L. Haas, P. Elder, C. B. Good, M. Shad, J. Conigliaro, and H. Pincus Racial Differences in the Treatment of Veterans With Bipolar Disorder Psychiatr Serv, December 1, 2005; 56(12): 1549 - 1555. [Abstract] [Full Text] [PDF]

				E. H. Pi and G. M. Simpson Psychopharmacology: Cross-Cultural Psychopharmacology: A Current Clinical Perspective Psychiatr Serv, January 1, 2005; 56(1): 31 - 33. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2003 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us